We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Medpace (MEDP) Advances While Market Declines: Some Information for Investors
Read MoreHide Full Article
In the latest close session, Medpace (MEDP - Free Report) was up +1.4% at $519.96. The stock outpaced the S&P 500's daily loss of 0.01%. On the other hand, the Dow registered a gain of 0.14%, and the technology-centric Nasdaq decreased by 0.46%.
Shares of the provider of outsourced clinical development services have appreciated by 19.81% over the course of the past month, outperforming the Medical sector's gain of 2.92%, and the S&P 500's loss of 1.4%.
The investment community will be closely monitoring the performance of Medpace in its forthcoming earnings report. The company is scheduled to release its earnings on July 22, 2026. It is anticipated that the company will report an EPS of $4.08, marking a 31.61% rise compared to the same quarter of the previous year. At the same time, our most recent consensus estimate is projecting a revenue of $678.51 million, reflecting a 12.47% rise from the equivalent quarter last year.
For the annual period, the Zacks Consensus Estimates anticipate earnings of $17.04 per share and a revenue of $2.79 billion, signifying shifts of +11.52% and +10.32%, respectively, from the last year.
Additionally, investors should keep an eye on any recent revisions to analyst forecasts for Medpace. These recent revisions tend to reflect the evolving nature of short-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.
The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. Right now, Medpace possesses a Zacks Rank of #2 (Buy).
Looking at its valuation, Medpace is holding a Forward P/E ratio of 30.09. This valuation marks a premium compared to its industry average Forward P/E of 15.24.
Meanwhile, MEDP's PEG ratio is currently 2.6. The PEG ratio bears resemblance to the frequently used P/E ratio, but this parameter also includes the company's expected earnings growth trajectory. Medical Services stocks are, on average, holding a PEG ratio of 1.4 based on yesterday's closing prices.
The Medical Services industry is part of the Medical sector. This group has a Zacks Industry Rank of 95, putting it in the top 39% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.
View the Zacks #1 Rank List
Image: Bigstock
Medpace (MEDP) Advances While Market Declines: Some Information for Investors
In the latest close session, Medpace (MEDP - Free Report) was up +1.4% at $519.96. The stock outpaced the S&P 500's daily loss of 0.01%. On the other hand, the Dow registered a gain of 0.14%, and the technology-centric Nasdaq decreased by 0.46%.
Shares of the provider of outsourced clinical development services have appreciated by 19.81% over the course of the past month, outperforming the Medical sector's gain of 2.92%, and the S&P 500's loss of 1.4%.
The investment community will be closely monitoring the performance of Medpace in its forthcoming earnings report. The company is scheduled to release its earnings on July 22, 2026. It is anticipated that the company will report an EPS of $4.08, marking a 31.61% rise compared to the same quarter of the previous year. At the same time, our most recent consensus estimate is projecting a revenue of $678.51 million, reflecting a 12.47% rise from the equivalent quarter last year.
For the annual period, the Zacks Consensus Estimates anticipate earnings of $17.04 per share and a revenue of $2.79 billion, signifying shifts of +11.52% and +10.32%, respectively, from the last year.
Additionally, investors should keep an eye on any recent revisions to analyst forecasts for Medpace. These recent revisions tend to reflect the evolving nature of short-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.
The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. Right now, Medpace possesses a Zacks Rank of #2 (Buy).
Looking at its valuation, Medpace is holding a Forward P/E ratio of 30.09. This valuation marks a premium compared to its industry average Forward P/E of 15.24.
Meanwhile, MEDP's PEG ratio is currently 2.6. The PEG ratio bears resemblance to the frequently used P/E ratio, but this parameter also includes the company's expected earnings growth trajectory. Medical Services stocks are, on average, holding a PEG ratio of 1.4 based on yesterday's closing prices.
The Medical Services industry is part of the Medical sector. This group has a Zacks Industry Rank of 95, putting it in the top 39% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.